Yersinia enterocolitica ghost with msbB mutation provides protection and reduces proinflammatory cytokines in mice.

[1]  M. Skurnik,et al.  Bacterial Cell Surface Structures in Yersinia enterocolitica , 2012, Archivum Immunologiae et Therapiae Experimentalis.

[2]  H. Liu,et al.  Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response. , 2010, Canadian journal of microbiology.

[3]  J. Bengoechea,et al.  Role of Lipid A Acylation in Yersinia enterocolitica Virulence , 2010, Infection and Immunity.

[4]  T. Jones,et al.  Yersinia pseudotuberculosis and Y. enterocolitica Infections, FoodNet, 1996–2007 , 2010, Emerging infectious diseases.

[5]  Wei Sun,et al.  Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica. , 2009, Vaccine.

[6]  Shiyun Chen,et al.  OmpR positively regulates urease expression to enhance acid survival of Yersinia pseudotuberculosis. , 2009, Microbiology.

[7]  M. S. Di Genaro,et al.  IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: implications for its use as oral carrier vaccine. , 2008, Vaccine.

[8]  J. Heesemann,et al.  Yersinia enterocolitica Yop mutants as oral live carrier vaccines. , 2008, Vaccine.

[9]  A. Blom,et al.  Yersinia enterocolitica Serum Resistance Proteins YadA and Ail Bind the Complement Regulator C4b-Binding Protein , 2008, PLoS pathogens.

[10]  D. Maskell,et al.  Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen. , 2008, FEMS immunology and medical microbiology.

[11]  I. Autenrieth,et al.  Yersinia enterocolitica: subversion of adaptive immunity and implications for vaccine development. , 2008, International journal of medical microbiology : IJMM.

[12]  I. Autenrieth,et al.  The Yersinia enterocolitica Invasin Protein Promotes Major Histocompatibility Complex Class I- and Class II-Restricted T-Cell Responses , 2006, Infection and Immunity.

[13]  A. Hensel,et al.  T cell-specific immune response induced by bacterial ghosts. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[14]  M. Biedzka-Sarek,et al.  Role of YadA, Ail and Lipopolysaccharide in Serum Resistance of Yersinia enterocolitica Serotype O:3 , 2004, Infection and Immunity.

[15]  V. Kutyrev,et al.  Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. , 2003, Vaccine.

[16]  W. Lubitz,et al.  Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. , 2003, Vaccine.

[17]  I. Autenrieth,et al.  Attenuated Yersiniaenterocolitica Mutant Strains Exhibit Differential Virulence in Cytokine-Deficient Mice: Implications for the Development of Novel Live Carrier Vaccines , 2003, Infection and Immunity.

[18]  R. Coler,et al.  Taking toll: lipid A mimetics as adjuvants and immunomodulators. , 2002, Trends in microbiology.

[19]  E. Rietschel,et al.  Invited review: Bacterial lipopolysaccharides and innate immunity , 2001 .

[20]  S. Gronow,et al.  Invited review: Lipopolysaccharide biosynthesis: which steps do bacteria need to survive? , 2001 .

[21]  G. Cornelis,et al.  Molecular and cell biology aspects of plague. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Heesemann,et al.  Rational Live Oral Carrier Vaccine Design by Mutating Virulence-Associated Genes of Yersinia enterocolitica , 1999, Infection and Immunity.

[23]  S. Schaffelhofer,et al.  Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity. , 1999, Microbial pathogenesis.

[24]  G. Dougan,et al.  Construction and characterisation of a Yersinia enterocolitica O:8 ompR mutant. , 1998, FEMS microbiology letters.

[25]  I. Charles,et al.  A lethal role for lipid A in Salmonella infections , 1998, Molecular microbiology.

[26]  E. Bottone.  Yersinia enterocolitica: the charisma continues , 1997, Clinical microbiology reviews.

[27]  E. Bottone.  Yersinia enterocolitica: the charisma continues. , 1997 .

[28]  J. Heesemann,et al.  Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen , 1997, Infection and immunity.

[29]  A. Hensel,et al.  Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. , 1997, Vaccine.

[30]  A. Noll,et al.  Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12 , 1996, Infection and immunity.

[31]  G. Dougan,et al.  Construction and Characterization of a Yersinia , 1996 .

[32]  I. Autenrieth,et al.  Role of plasmid-encoded antigens of Yersinia enterocolitica in humoral immunity against secondary Y. enterocolitica infection in mice. , 1993, Microbial pathogenesis.

[33]  A. Paerregaard.  Interactions between Yersinia enterocolitica and the host with special reference to virulence plasmid encoded adhesion and humoral immunity. , 1992, Danish medical bulletin.

[34]  U. Bläsi,et al.  Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E , 1990, Journal of bacteriology.

[35]  E. Rietschel,et al.  Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. , 1985, European journal of biochemistry.

[36]  K. Kaneko,et al.  Cross-resistance to fecal excretion of Yersinia enterocolitica in mice by oral vaccination of killed cells , 1983, Infection and immunity.

[37]  S. Gronow,et al.  Lipopolysaccharide biosynthesis: which steps do bacteria need to survive? , 2001, Journal of endotoxin research.

[38]  E. Rietschel,et al.  Bacterial lipopolysaccharides and innate immunity. , 2001, Journal of endotoxin research.

[39]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[40]  C. Raetz,et al.  Biochemistry of endotoxins. , 1990, Annual review of biochemistry.

[41]  T. L. Cover,et al.  Yersinia enterocolitica. , 1989, The New England journal of medicine.